# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...
JP Morgan analyst Eric Joseph maintains Vir Biotechnology (NASDAQ:VIR) with a Neutral and raises the price target from $10 t...
Needham analyst Joseph Stringer reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $15 price target.
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1....
On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the "Company&...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $110 pri...